Side-by-side · Research reference
IpamorelinvsP21
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 1HUMAN-REVIEWED21/57 cited
BAnimal-MechanisticHUMAN-REVIEWED8/36 cited
Ipamorelin
Selective GHRP · Ghrelin Mimetic
SQ · Multiple sites · 1–3×/day
P21
CNTF-Derived Neuropeptide · Animal Model Evidence
Animal onlyEvidence level
SQ · Site unspecified · Frequency unknown
01Mechanism of Action
Parameter
Ipamorelin
P21
Primary target
Ghrelin receptor (GHS-R1a) on anterior pituitaryRaun 1998
CNTF receptor alpha (CNTFRα) / LIF receptor (LIFR) / gp130 complex on neural stem cells
Pathway
GHS-R1a binding → Gαq/11 → ↑intracellular Ca²⁺ → GH vesicle exocytosisRaun 1998Bowers 1991
CNTF mimetic → CNTFRα/LIFR/gp130 heterotrimer → JAK/STAT3 signaling → neurogenesis, stem cell proliferation, neuroprotection
Downstream effect
GH pulse amplification, IGF-1 elevation, recovery and lipolytic effectsBowers 2002
Increased neural stem cell self-renewal, globose basal cell activation (Mash1+ cells), olfactory sensory neuron regeneration, hippocampal neurogenesis, neuroprotection in developmental disorders
Origin
Pentapeptide H-Aib-His-D-2-Nal-D-Phe-Lys-NH₂; rationally designed for ghrelin-receptor selectivityRaun 1998
Small-molecule peptide mimetic derived from full-length ciliary neurotrophic factor (CNTF), designed to retain receptor activation with improved pharmacokineticsMottolese 2024
Antibody development
Not reported in short-term studies
—
02Dosage Protocols
Parameter
Ipamorelin
P21
Standard dose
200–300 mcg per injectionRaun 1998
Anecdotal community range; clinical doses 1–3 mg IV in trials.
—
Frequency
1–3× per day
Once daily pre-sleep is most common; twice or thrice for advanced users.
—
Lower / starter dose
100 mcg per dose
—
Evidence basis
Phase 1 + clinical practiceRaun 1998Sigalos 2018
Animal models only
CDKL5 KO mice, methimazole-induced olfactory injury, CNTF-/- knockout models.Mottolese 2024Cox 2026Jia 2020
Duration
8–12 weeks on / 4 weeks off (anecdotal)
GHS-R desensitisation reported with continuous dosing.
Not specified
Reconstitution
Bacteriostatic water; typical 2 mL per 5 mg vial
—
Timing
Pre-sleep + fasted preferred; 30 min away from food
—
Human dosing
—
No established protocol
No clinical trial data available.
Animal models (mice)
—
Dose and route not specified in abstractsMottolese 2024Jia 2020
In vitro and in vivo studies demonstrate efficacy; precise dosing protocols not disclosed.
Route
—
Presumed subcutaneous or intraperitoneal (animal studies)
04Side Effects & Safety
Parameter
Ipamorelin
P21
Hunger
Mild appetite increase via ghrelin-receptor crosstalk
—
Injection site reaction
Mild irritation possible
—
GH excess (overdose)
Joint pain, edema, insulin resistance
—
IGF-1 elevation
Dose-dependent; monitor with chronic high-dose use
—
Cancer risk
Theoretical via GH/IGF-1 axis; contraindicated in active malignancy
—
Pregnancy / OB
Avoid
—
Human safety data
—
None available
No clinical trials in humans.
Animal tolerability
—
Well-tolerated in mouse models; no toxicity reported in available abstracts
Theoretical risks
—
Uncontrolled stem cell proliferation, immune response to peptide, unknown long-term CNS effects
Absolute Contraindications
Ipamorelin
- ·Active malignancy or cancer history
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
P21
- ·Use in humans not validated
Relative Contraindications
Ipamorelin
- ·Untreated diabetes
- ·Severe insulin resistance
- ·Concurrent corticosteroid use (theoretical desensitisation)
P21
- ·Active malignancy (theoretical — neurotrophic signaling may affect tumour growth)
- ·Pregnancy or lactation (no safety data)
05Administration Protocol
Parameter
Ipamorelin
P21
1. Reconstitution
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL. Roll gently. Solution should be clear.
Not established. No FDA approval, no clinical trial data.
2. Injection site
Subcutaneous, abdomen or thigh. Rotate sites. Pinch fat for shallow SQ delivery.
In vivo studies used systemic administration (route not specified in abstracts) in mouse models of neurodegeneration, olfactory injury, and CDKL5 deficiency disorder. In vitro studies used primary cell cultures.
3. Timing
Pre-sleep optimal — aligns with natural GH pulse. Some protocols add a morning fasted dose.
—
4. Storage
Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.
—
5. Needle
29–31G, 4–8 mm insulin syringe.
—
06Stack Synergy
Ipamorelin
+ Tesamorelin
StrongIpamorelin (GHRP) + tesamorelin (GHRH analogue) is the textbook dual-axis GH stack. They activate two distinct pituitary receptors — the ghrelin receptor and the GHRH receptor — producing a synergistic GH pulse larger than either alone. Ipamorelin's selectivity (no cortisol/prolactin spike) makes it the ideal GHRP partner for long-term protocols.
- Ipamorelin
- 200–300 mcg SQ · pre-sleep
- Tesamorelin
- 2 mg SQ · same injection · pre-sleep
- Primary benefit
- Maximal GH pulsatility, fat loss, recovery, sleep depth
+ CJC-1295 (no DAC)
StrongCJC-1295 (no DAC) is a short-acting GHRH analogue. Combined with ipamorelin (GHRP), the pulse is amplified across both receptor systems with timing similar to native physiology. Without the DAC modification, the stack maintains sharp peaks rather than the sustained elevation seen with CJC-1295-DAC + ipamorelin.
- Ipamorelin
- 200–300 mcg SQ · pre-sleep
- CJC-1295 (no DAC)
- 100 mcg SQ · same injection
- Primary benefit
- Pulsatile GH stimulation matching physiological pattern
P21
— no documented stacks